CD274 and lung cancer: Since 2015, the clinical practice of immunotherapy for advanced lung cancer has seen significant advances, especially PD-1/PD-L1 inhibitors have improved the survival outcomes in patients with NSCLC, with approximately 20% of patients having sustained responses [32, 33].